en · de · es · fr · pt
sr9009-notes.peptides6608.com › Faq › Background And Research Status — Hands-On Walkthrough

Background And Research Status — Hands-On Walkthrough

By Editorial Desk · published 2026-06-01 · last reviewed 2026-07-05 · Faq

SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Related pages on this site

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Supporting material

==== Nintedanib ==== Nintedanib is a triple angiokinase inhibitor that targets receptor tyrosine kinases involved in the regulation of angiogenesis: fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), which have also been implicated in the pathogenesis of fibrosis and IPF. In both phase III trials, nintedanib reduced the decline in lung function by approximately 50% over one year. It was approved by the US FDA in October 2014 and authorised in Europe in January 2015.

Pellagra is a disease caused by a lack of the vitamin niacin (vitamin B3). Symptoms include inflamed skin, diarrhea, dementia, and sores in the mouth. Areas of the skin exposed to friction and radiation are typically affected first. Over time, affected skin may become darker, stiffen, peel, or bleed. The two main types of pellagra are primary and secondary. Primary pellagra is due to a diet that does not contain enough niacin and tryptophan. Secondary pellagra is due to a poor ability to use the niacin within the diet. This can occur as a result of alcoholism, long-term diarrhea, carcinoid syndrome, Hartnup disease, and a number of medications such as isoniazid. Diagnosis is typically based on symptoms and may be assisted by urine testing. Treatment is with either nicotinic acid or nicotinamide supplementation. Improvements typically begin within a few days. General improvements in diet are also frequently recommended. Decreasing sun exposure via sunscreen and proper clothing is important while the skin heals. Without treatment, death may occur. The disease occurs most commonly in the developing world, often as a disease of poverty associated with malnutrition, specifically sub-Saharan Africa.

Ancient pyramidical structures, mausoleums, ruined cities and stone walls, such as the Wargaade Wall, are evidence of an old civilisation that once thrived in the Somali peninsula. This civilisation enjoyed a trading relationship with ancient Egypt and Mycenaean Greece since the second millennium BC, supporting the hypothesis that Somalia or adjacent regions were the location of the ancient Land of Punt. The Puntites native to the region traded myrrh, spices, gold, ebony, short-horned cattle, ivory and frankincense with the Egyptians, Phoenicians, Babylonians, Indians, Chinese and Romans through their commercial ports. An Egyptian expedition sent to Punt by the 18th dynasty Queen Hatshepsut is recorded on the temple reliefs at Deir el-Bahari, during the reign of the Puntite King Parahu and Queen Ati. In the classical era, the Macrobians, who may have been ancestral to Somalis, established a powerful kingdom that ruled large parts of modern Somalia. They were reputed for their longevity and wealth, and were said to be the "tallest and handsomest of all men". The Macrobians were warrior herders and seafarers. According to Herodotus' account, the Persian Emperor Cambyses II, upon his conquest of Egypt in 525 BC, sent ambassadors to Macrobia, bringing luxury gifts for the Macrobian king to entice his submission.

The coenzyme NAD+ was first discovered by the British biochemists Arthur Harden and William John Young in 1906. They noticed that adding boiled and filtered yeast extract greatly accelerated alcoholic fermentation in unboiled yeast extracts. They called the unidentified factor responsible for this effect a coferment. Through a long and difficult purification from yeast extracts, this heat-stable factor was identified as a nucleotide sugar phosphate by Hans von Euler-Chelpin. In 1936, the German scientist Otto Heinrich Warburg showed the function of the nucleotide coenzyme in hydride transfer and identified the nicotinamide portion as the site of redox reactions. Vitamin precursors of NAD+ were first identified in 1938, when Conrad Elvehjem showed that liver has an "anti-black tongue" activity in the form of nicotinamide. Then, in 1939, he provided the first strong evidence that nicotinic acid is used to synthesize NAD+. In the early 1940s, Arthur Kornberg was the first to detect an enzyme in the biosynthetic pathway. In 1949, the American biochemists Morris Friedkin and Albert L. Lehninger proved that NADH linked metabolic pathways such as the citric acid cycle with the synthesis of ATP in oxidative phosphorylation. In 1958, Jack Preiss and Philip Handler discovered the intermediates and enzymes involved in the biosynthesis of NAD+; salvage synthesis from nicotinic acid is termed the Preiss-Handler pathway. In 2004, Charles Brenner and co-workers uncovered the nicotinamide riboside kinase pathway to NAD+. The non-redox roles of NAD(P) were discovered later.

=== Negative factors === Diabetes, cardiovascular disease, urgent initiation, inadequate dialysis (Kt/V <1.2), infections. COVID-19 increased mortality in 2020 but rates declined by 2022. In low-resource settings, median survival may be ~1.5 years due to access barriers.

Sources: en.wikipedia.org

Notes from published material

After its inception, the group grew quickly and, by late summer in 1943, It was claimed to have 15,000 to 20,000 active men and women military fighters and 50,000 more in reserve. These fighters' weaponry was obtained primarily by stealing it from battlefields and downed planes left behind by the Japanese, Filipinos, and Americans. They fought Japanese troops, worked to subvert the Japanese tax-collection service, intercepted food and supplies to the Japanese troops, and created a training school where they taught political theory and military tactics based on Marxist ideas. In areas that the group controlled, they set up local governments (Sandatahang Tanod ng Bayan, Barrio United Defense Corps) and instituted land reforms, dividing up the largest estates equally among the peasants and often killing the landlords. In some cases, however, landlords were welcomed as participants in Huk resistance, swayed by anti-Japanese sympathies. PKP organizers quickly went to work to set up BUDCs in Huk controlled barrios, which contributed to its success as a resistance army, although in reality there was an overlap between independently formed barrio governments, "neighborhood committees" set up by the Japanese, and BUDCs. The Huk movement was notable for its inclusion of women peasants, who advocated for inclusion in the movement in resistance to the word of Japanese war atrocities against women, including rape and mutilation. Many of these women fought, but the majority of the resistance remained in villages, collecting supplies and intelligence.

Although vitamin A was not confirmed as an essential nutrient and a chemical structure described until the 20th century, written observations of conditions created by deficiency of this nutrient appeared much earlier in history. Sommer classified historical accounts related to vitamin A and/or manifestations of deficiency as follows: "ancient" accounts; 18th- to 19th-century clinical descriptions (and their purported etiologic associations); early 20th-century laboratory animal experiments, and clinical and epidemiologic observations that identified the existence of this unique nutrient and manifestations of its deficiency.

Paralytic peptides are a family of short (23 amino acids) insect peptides that halt metamorphosis of insects from larvae to pupae. These peptides contain one disulphide bridge. The family includes growth-blocking peptide (GBP) of Mythimna separata (Oriental armyworm) and the paralytic peptides from Manduca sexta (tobacco hawkmoth), Heliothis virescens (noctuid moth), and Spodoptera exigua (beet armyworm) as well as plasmatocyte-spreading peptide (PSP1).

== Businesses and organizations == Danish Geodata Agency (Geodatastyrelsen) General Staff (Sweden), a former agency of the Government of Sweden German Steel Trust, a German steel company Gerolsteiner (cycling team) Gesellschaft für Sport und Technik, a former East German mass organization providing mandatory pre-military training Groupe socialiste des travailleurs du Québec, a defunct political movement in Canada Gulf States Toyota Distributors, an American automobile distributor SIES Graduate School of Technology, in Mumbai, India

=== Red blood cell transfusions === Blood transfusions are the main treatment approach for prolonging life. Donated healthy red blood cells have a functional life of 4 to 6 weeks before they wear out and are broken down in the spleen. Regular transfusions every three to four weeks are necessary in order to maintain hemoglobin at a healthy level. Transfusions come with risks including iron overload, the risk of acquiring infections, and the risk of immune reaction to the donated cells (alloimmunization).

Sources: en.wikipedia.org

Background from the literature

Efforts are ongoing to find medications that either return the ability to make dystrophin or utrophin. Other efforts include trying to block the entry of calcium ions into muscle cells. Recent reports have revealed gut microbiome dysbiosis influencing muscle pathophysiology through the immune system of dystrophin‐deficient mice and managing of gut dysbiosis with sodium butyrate supplementation (NaB) in mdx mice is reported with rescuing muscle strength and halting inflammation. In human clinical studies, epigenetic manipulation as a potential mechanism through gut microbiome balancing yielding clinically encouraging outcome have been reported, warranting further in-depth evaluation in this direction.

If references are made, the Court of Justice will give a preliminary ruling, in order for the member state court to conclude the case and award a remedy. The right to an effective remedy is a general principle of EU law, enshrined in the Charter of Fundamental Rights article 47. Most of the time Regulations and Directives will set out the relevant remedies to be awarded, or they will be construed from the legislation according to the practices of the member state. It could also be that the government is responsible for failure to properly implement a Directive or Regulation, and must therefore pay damages. In Francovich v Italy, the Italian government had failed to set up an insurance fund for employees to claim unpaid wages if their employers had gone insolvent, as the Insolvency Protection Directive required. Francovich, the former employee of a bankrupt Venetian firm, was therefore allowed to claim 6 million Lira from the Italian government in damages for his loss. The Court of Justice held that if a Directive would confer identifiable rights on individuals, and there is a causal link between a member state's violation of EU and a claimant's loss, damages must be paid. The fact that the incompatible law is an Act of Parliament is no defence. So, in Factortame it was irrelevant that Parliament had legislated to require a quota of British ownership of fishing vessels in primary legislation.

== Further reading == Sarah Steinbach and Reto Neiger: Chronische Nierenerkrankung: In: Hans Lutz et al. (Ed.): Krankheiten der Katze. Enke, 5. Aufl. 2014, ISBN 978-3-8304-1243-4, S. 751–755. Gregory F. Grauer: Chronic renal failure. In: R. W. Nelson und C. G. Couto (Hrsg.): Small animal internal medicine. Mosby, 3. 2003, ISBN 0-323-01724-X, p. 615–623.

== Bibliography == Alt-Kutscha : vol.1 Archived 2020-01-27 at the Wayback Machine Arlt, Robert; Hiyama, Satomi (2013). "Fruits of Research on the History of Central Asian Art in Berlin: The Identification of Two Sermon Scenes from Kizil Cave 206 (Fußwaschungs- höhle)". Indo-Asiatische Zeitschrift (Berlin) 17: 16–26. Beckwith, Christopher (1993). The Tibetan Empire in Central Asia: A History of the Struggle for Great Power Among Tibetans, Turks, Arabs, and Chinese During the Early Middle Ages. Princeton University Press. ISBN 0-691-02469-3. Beckwith, Christopher I. (2009). Empires of the Silk Road: A History of Central Eurasia from the Bronze Age to the Present. Princeton University Press. ISBN 978-0-691-13589-2. Grousset, René (1970). The Empire of the Steppes: A History of Central Asia. Rutgers University Press. ISBN 978-0-8135-1304-1. Grünwedel, Albert (1912). Altbuddhistische Kultstätten in Chinesisch-Turkistan: Bericht über archäologische Arbeiten von 1906 bis 1907 bei Kuča, Qarašahr und in der Oase Turfan. Berlin: Arthur-Baessler-Institut. Doi:10.20676/00000191. Hopkirk, Peter (1984). Foreign devils on the silk road : the search for the lost cities and treasures of Chinese Central Asia. Amherst: University of Massachusetts Press. ISBN 9780870234354. Hiyama, Satomi 檜山智美 (2013) Study on the first-style murals of Kucha: Analysis of some motifs related to the Hephthalite's period クチャの第一樣式壁畫に見られるエフタル期のモチーフについて (“Kucha no daiichi yōshiki hekiga ni mirareru Efutaru ki no mochīfu ni tsuite”).

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network